Abzena provides proprietary technologies and value-added services to enable the development of better biopharmaceuticals. The company comprises two wholly owned subsidiary businesses – PolyTherics and Antitope – which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade, including the top 10 pharma, large and small biotech, and academic groups. Abzena is listed on the AIM segment of the London Stock Exchange under the symbol ABZA.